SCHEMBL1554497

SCHEMBL1554497

COc1ccc(C(=O)O)c(C)c1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
MAPT P10636 3/20 0.51
TDP1 Q9NUW8 1/20 0.51
MYC P01106 1/20 0.46
CDC25B P30305 1/20 0.45
KDM4E B2RXH2 5/20 0.43
HTT P42858 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
MAPK1 P28482 3/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837874 0.85 ALDH1A1 (0.56) ALDH1A1MAPTTDP1MYCCDC25B
SCHEMBL1203086 0.85 ALDH1A1 (0.59) ALDH1A1MAPTTDP1MYCCDC25B
SCHEMBL732725 0.82 MAPT (0.61) ALDH1A1MAPTTDP1MYCCDC25B
SCHEMBL1553837 0.81 MAPT (0.66) ALDH1A1MAPTTDP1MYCCDC25B
SCHEMBL23925274 0.80 ALDH1A1 (0.54) ALDH1A1MAPTTDP1MYCCDC25B
SCHEMBL31494238 0.80 GABRP (0.50) ALDH1A1MAPTTDP1MYCKDM4E
SCHEMBL2921220 0.80 GABRP (0.50) ALDH1A1MAPTTDP1MYCKDM4E
SCHEMBL17874169 0.80 ALDH1A1 (0.39) ALDH1A1MAPTTDP1KDM4EHTT
SCHEMBL2425023 0.79 MAPT (0.68) ALDH1A1MAPTTDP1MYCCDC25B
SCHEMBL57368 0.79 MAPT (0.62) ALDH1A1MAPTTDP1MYCCDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934307-B1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE AVENTIS PHARMA LTD (GB) 2011-04-27 EP disclosed
US-20100255934-A1 COMPOSITIONS FOR GOLF EQUIPMENT ACUSHNET COMPANY 2010-10-07 US disclosed
EP-2223920-A2 Substituted azabicyclic compounds Aventis Pharma Limited (GB) 2010-09-01 EP disclosed
US-7709590-B2 Compositions for golf equipment ACUSHNET COMPANY (US) 2010-05-04 US disclosed
US-7550549-B2 Compositions for golf equipment ACUSHNET COMPANY (US) 2009-06-23 US disclosed
US-7417106-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-08-26 US disclosed
US-20080188326-A1 Compositions for Golf Equipment ACUSHNET COMPANY 2008-08-07 US disclosed
US-7378483-B2 Compositions for golf equipment ACUSHNET COMPANY (US) 2008-05-27 US disclosed
US-20080064527-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2008-03-13 US disclosed
US-7329675-B2 Substituted azabicyclic compounds AVENTIS PHARMA LIMITED (GB) 2008-02-12 US disclosed
US-20040220356-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed
US-20040220378-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed
US-20040220377-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed
US-20040220376-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed
US-20040220373-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed
US-20040220357-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed
US-6800645-B1 INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE AVENTIS PHARMA LIMITED (GB) 2004-10-05 US disclosed
US-20020173527-A1 Substituted azabicyclic compounds ASTLES PETER CHARLES (GB) 2002-11-21 US disclosed
US-6303600-B1 USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY RHONE-POULENC RORER LIMITED (GB) 2001-10-16 US disclosed
CN-1302287-A Bioreductive cytotoxic agents SHIONOGI BIORES CORP (US) 2001-07-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173527-A1 Substituted azabicyclic compounds CBR1, NOX1, POR ALDH1A1 375/4885MAPT 4862/4885TDP1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.